Synergistic anticancer effects of Chrysin and trastuzumab in HER2-Positive breast cancer cells
Abstract HER2-positive breast cancer is an aggressive subtype with limited therapeutic options. Trastuzumab, a monoclonal antibody targeting the HER2 receptor, has improved clinical outcomes; however, its efficacy remains a critical challenge in the HER2-positive model. This study investigated the p...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Portfolio
2025-11-01
|
| coleção: | Scientific Reports |
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1038/s41598-025-25098-x |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|